Copy to clipboard 
Nanovis marked a milestone of 20,000 nanotechnology-enhanced devices successfully implanted in patients with no reports of infections or pseudoarthrosis in the FDA MAUDE database. Nanovis’ proprietary nanoVIS Ti Surface Technology has demonstrated its ability to increase and accelerate bone growth and healing.
Achieving 20,000 implanted devices marks a significant achievement for Nanovis, underscoring the value of its nanotechnology solutions in driving improved patient outcomes. Nanovis is distinguished as the only private company with an FDA-designated nanotechnology surface that is commercially scaled and available to companies across spine, orthopedics and dental markets.
Unlike other companies that use “nano” in their product name or as a marketing term, Nanovis’ FDA nanotechnology designation reflects a rigorous process in which surfaces are engineered at scales smaller than 100 nanometers to produce a biological effect at the implant surface. This distinction is explicitly noted in the product’s Instructions for Use, underscoring the genuine nanotechnological enhancement of Nanovis devices.
“It has been great to witness the adoption and success of nanotechnology-designated surfaces in spine surgery,” said Jeff Shepherd, Nanovis’ Chief Commercial Officer. “Nanovis is the only private company who has made their nanotechnology surface commercially available to companies in spine, orthopedics, and dental. Our human clinical success in spine, our in vivo and in vitro data sets, our FDA label to include comparative surface data, and our nanotechnology master files can accelerate FDA clearances and improve commercial performance. We look forward to partnering with companies to bring this superior nanotechnology surface to their implants and portfolios.”
“Our vision is innovation, and our mission is to be the market leader in developing and producing implant nano surface technology,” said Brian More, CEO of Nanovis. “I am proud of the Nanovis team, our perseverance and our collaboration with Sites Medical and Micropulse over the last decade in bringing our vision to fruition. Implant surface technologies should promote holistic healing, which includes implant biological integration and reduced infection risk. I am excited to see the market-changing impact our team will experience as we introduce a pipeline of surface technologies to address the unique problems in the various market segments.”
Nanovis’ nanoVIS Ti, available through Nanovis Surface Technologies, leverages four core pillars to enhance bone growth and healing: reducing bacterial colonization, improving inflammatory response, increasing vascularization and accelerating osseointegration.
To date, Nanovis has cleared eight products with nanotechnology designation, covering both commercially pure titanium and titanium alloys. The company has also successfully integrated its nanotechnology surface on macroporous and micron-roughened implants, broadening its availability to companies in orthopedics, spine and dental sectors.
Source: Nanovis
